KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Other financing activities for 8 consecutive years, with -$9000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other financing activities changed N/A year-over-year to -$9000.0; the TTM value through Mar 2026 reached -$9000.0, up 99.71%, while the annual FY2025 figure was $2.4 million, N/A changed from the prior year.
  • Other financing activities hit -$9000.0 in Q1 2026 for Alnylam Pharmaceuticals, up from -$1.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $8.3 million in Q3 2023 and bottomed at -$16.3 million in Q4 2023.
  • Average Other financing activities over 4 years is $2.6 million, with a median of $4.0 million recorded in 2023.
  • Year-over-year, Other financing activities soared 137.48% in 2022 and then crashed 317.77% in 2023.
  • Alnylam Pharmaceuticals' Other financing activities stood at $7.5 million in 2022, then plummeted by 317.77% to -$16.3 million in 2023, then skyrocketed by 89.16% to -$1.8 million in 2024, then surged by 99.49% to -$9000.0 in 2026.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$9000.0, -$1.8 million, and -$1.3 million for Q1 2026, Q3 2024, and Q2 2024 respectively.